Home » Market News » DirectorsTalk Highlights » Oncimmune Holdings plc Regulatory Approval in Israel for EarlyCDT®-Lung
Oncimmune Holdings PLC

Oncimmune Holdings plc Regulatory Approval in Israel for EarlyCDT®-Lung

Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announced that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of EarlyCDT-Lung in Israel.

Dr Adam M Hill, CEO of Oncimmune commented: “We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel.”

On an age standardised basis, Israel’s lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. Lung cancer is responsible for more cancer-related deaths than any other cancer in Israel.1

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.